/COMUNICAE/
The Spanish company has developed a natural biocompound with rosemary extract already validated against colon cancer. It has been developed by scientists from the Autonomous University, the IMDEA Food and the Hospital Infanta Sofia
The Spanish company Forchronic will perform new clinical trials of its patented natural biocomposite based on supercritical extract of rosemary in flu patients in 2020. It also contemplates the possibility of extending its tests to check its effects on the coronavirus.
The compound developed by Forchronic has a marked enhancer effect of the immune system activating the patient's innate response capacity against pathogens. Clinical trials show that biocomposed favors the production of several types of cells such as monocytes and cytokines and the functional maturation of lymphocytes, all of them involved in the immune system.
Colon cancer and other tumors
The Forchronic research team consists of members of the bioactive lipid team of the Autonomous University of Madrid, the molecular oncology group of the IMDEA Food Institute and the Oncology Service of the Infanta Sofia Hospital. The new compound has already been tested in patients with colon cancer. The results show that it inhibits metabolic paths associated with tumor growth thus confirming the effects achieved in animals. In addition, researchers are also in the process of verifying the validity of their bioactive compound in tumors associated with breast and lung cancer with clinical trials in people affected by these pathologies.
Along with its effectiveness in personalized precision treatments against cancer, the compound has a clear protective action of the immune system so Forchronic is completing the tests to verify its effects on autoimmune diseases such as rheumatoid arthritis, type I diabetes, psoriasis, celiac disease and multiple sclerosis.
Gripe and coronavirus
Beyond the above-mentioned diseases, Forchronic will perform new clinical trials in flu patients throughout this exercise and contemplates the possibility of extending its trials to check the effects on coronavirus. As Enrique Sainz, CEO of Forchronic explains, “the flu triggers a complex immune system response that involves the activation of macrophages, cytokines and lymphocytes, among other cells, which can be enhanced by the action of this biocomposed. We want to know what impact our formula can achieve in the fight against flu and we do not rule out expanding the trials against coronavirus as it comes from diseases with coincidental aspects.”
Flu is a disease with special interest to the researchers of the firm because of its high prevalence. It should be borne in mind that in 2018 there were almost 800,000 cases of this disease in Spain, 52,000 admitted and 15,000 killed.
After eight years of research the Forchronic formula has recently received the concession as a European patent and the company believes it will be able to market it in this exercise. Several companies in the pharmaceutical sector and clinical nutrition have already been interested in a possible agreement.
Forchronic
Forchronic is a company promoted by the investment society CanaanResearch and Investment, the Autonomous University of Madrid, the IMDEA Food Institute and the Infanta Sofia University Hospital. Its objective is research in Precision Nutrition for the development of nutraceuticals that allow personalization in the treatment of the patient from a genetic and physiological point of view to achieve maximum effectiveness.
Forchronic will test its new flu biocomposed and value expanding trials against coronavirus
The Spanish company has developed a natural biocompound with rosemary extract already validated against colon cancer. It has been developed by scientists from
nails
en
https://cdnimages.juegosboom.com/nails-trends.com/1220/dbmicrodb2-nails-forchronic-will-test-its-new-flu-biocomposed-and-value-expanding-trials-against-coronavirus-1522-0.jpg
2023-04-11
Acording with the Digital Millennium Copyright Act (“DMCA”), Pub. L. 105-304 If you believe that your copyrighted work is being infringed, notify our team at the email [email protected]